Chemotherapy for squamous cell carcinoma of head and neck: The future is now

Annals of Oncology

Volumn 7, Issue 1, 1996, Pages 15-29

  Vokes, E E ^a,c   Athanasiadis, I ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b UNIVERSITY OF ATHENS   (Greece)

^c UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

Chemotherapy; Head and neck cancer

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CISPLATIN; DOCETAXEL; FLUOROURACIL; GEMCITABINE; IFOSFAMIDE; METHOTREXATE; NAVELBINE; PACLITAXEL; TOPOTECAN;

BONE MARROW SUPPRESSION; FUTUROLOGY; HEAD AND NECK CANCER; HUMAN; MUCOSA INFLAMMATION; PRIORITY JOURNAL; REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 0030065644     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/oxfordjournals.annonc.a010467     Document Type: Review

References (152)

1. Vokes EE, Weichselbaum RR, Lippman S et al. Head and neck cancer. N Engl J Med 1993; 328: 184-94.
2. Kotwall C, Sako K, Razack MS et al. Metastatic pattern in squamous cell cancer of the head and neck. Am J Surg 1987; 154: 439-42.
3. Zbáren P, Lehmann W. Frequency and sites of distant metastases in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 1987; 113: 762-4.
4. Fearon ER, Vogelstein B. A genetic model of colorectal tumorigenesis. Cell 1991; 61: 759-67.
5. Lotan R, Xu XC, Lippman SM et al. Suppression of retinoic acid receptor-α in premalignant oral lesions and its up-regulation by isotretinoin, N Engl J Med 1995; 332: 1405-10.
6. Van Dyke DL, Worsham MJ, Benninger MS et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosom Cancer 1994; 9: 192-206.
7. Nawroz H, van der Riet P, Hruban RH et al. Allelotype of head and neck squamous cell carcinoma. Cancer Res 1994; 54:1152-5.
8. Ahsee KW, Cooke TG, Pickford IR. et al. An allelotype of squamous carcinoma of the head and neck using microsattelite markers. Cancer Res 1994; 54: 1617-21.
9. Cowan JM, Beckett MA, Ahmed-Swan S, Weichselbaum RR. Cytogenetic evidence of the multistep origin of head and neck squamous cell carcinomas. J Natl Cancer Inst 1992; 84: 793-6.
10. Van der Riet P, Nawroz H, Hruban RH et al. Frequent loss of chromosome 9p21-22 early in head and neck cancer progression. Cancer Res 1994; 54: 1156-8.
11. Shin DM, Kim J, Ro JY et al. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res 1994; 54: 321-6.
12. Boyle JO, Hakim J, Koch W et al. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res 1993; 53: 4477-80.
13. Hartwell LH, Kastan MB. Cell cycle control and cancer. Science 1994; 266: 1821-8.
14. Somers KD, Cartwright SL, Schechter GL. Amplifications of the int-2 gene in human head and neck squamous cell carcinomas. Oncogene 1990; 5: 915-20.
15. Jares P, Fernandez PL, Campo E et al. PRAD-1/Cyclin D1 gene amplification correlates with messenger RNA overexpression and tumor progression in human laryngeal carcinomas. Cancer Res 1994; 54: 4813-7.
16. Callender T, El-Nagger AK, Lee MS et al. PRAD-1 (CCND1)/cyclin D1 oncogene amplification in primary head and neck squamous cell carcinoma. Cancer 1994; 74: 152-8.
17. Weichselbaum RR, Dunphy EJ, Beckett MA et al. Epidermal growth factor receptor gene amplification and expression in head and neck cancer cell lines. Head Neck 1989; 11: 437-42.
18. Scambia G, Panici PB, Battaglia F et al. Receptors for epidermal growth factor and steroid hormones in primary laryngeal tumors. Cancer 1991; 67: 1347-51.
19. Santini J, Formento JL, Francoual M et al. Characterization, quantification, and potential clinical value of the epidermal growth factor receptor in head and neck squamous cell carcinomas. Head Neck 1991; 13: 132-9.
20. Dassonville O, Formento JL, Francoual, M et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol 1993; 11: 1873-8.
21. Brennan JA, Boyle JO, Koch WM et al. Association between cigarette smoking and mutation of the p53 gene in head and neck squamous carcinoma. N Engl J Med 1995; 332: 712-7.
22. Brachman DG, Graves D, Vokes E et al. Occurrence of p53 gene deletions and human papilloma virus infection in human head and neck cancer. Cancer Res 1992; 52: 4832-6.
23. Brennan JA, Mao L, Hruban RH et al. Molecular assessment of histopathologic staging. N Engl J Med 1995; 332: 429-35.
24. Mao L, Hruban RH, Boyle JB et al. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res 1994; 54: 1634-7.
25. Boyle JB, Mao L, Brennan JA et al. Gene mutations in saliva as molecular markers for head and neck squamous cell carcinomas. Am J Surg 1994; 168: 429-32.
26. Liu TJ, Zhang WW, Taylor DL et al. Growth suppression of human head and neck cancer cells by the introduction of a wild-type p53 gene via a recombinant adenovirus. Cancer Res 1994; 54: 3662-7.
27. Reiss M, Stash EB, Vellucci VG et al. Activation of the autocrine transforming growth factor α pathway in human squamous carcinoma cells. Cancer Res 1991; 51: 6254-62.
28. Pathmanathan R, Prasad U, Sadler R et al. Clonal proliferation of cells infected with Epstein-Barr Virus in preinvasive lesions related to nasopharyngeal carcinoma. N Engl J Med 1995; 333: 693-8.
29. Desgranges C, Wolf H, De-Thé G et al. Nasopharyngeal carcinoma. X. Presence of Epstein-Barr genomes in separated epithelial cells of tumors in patients from Singapore, Tunisia and Kenya. Int J Cancer 1975; 16: 7-15.
30. Liebowitz D. Nasopharyngeal carcinoma: The Epstein-Barr virus association. Semin Oncol 1994; 21: 366-75.
31. Brachman DG. Molecular biology of head and neck cancer. Semin Oncol 1994; 21: 359-5.
32. Schantz SP, Sessions RB, Harrison LB et al. Cancer of the head and neck. In De Vita VT, Hellman S, Rosenberg SA (eds): Principles and Practices of Oncology, 4th ed. Philadelphia, PA: Lippincott 1993; 574-672.
33. Pinto HA, Jacobs C. Chemotherapy for recurrent and metastatic head and neck cancer. Hematol Oncol Clin North Am 1991; 5: 667-86.
34. Forastiere AA, Metch B, Schuller DE et al. Randomized comparison of cisplatin plus fluorouracil and carboplatin plus fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: A Southwest Oncology Group study. J Clin Oncol 1992; 10: 1245-51.
35. Veronesi A, Zagonel V, Tirelli U et al. High-dose versus low-dose cisplatin in advanced head and neck squamous carcinoma: A randomized study. J Clin Oncol 1985; 3: 1105-8.
36. Morton RP, Rugman F, Dorman EB et al. Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: A randomized factorial phase III controlled trial. Cancer Chemother Pharmacol 1985; 15: 283-9.
37. Liverpool Head and Neck Oncology Group. A phase III randomized trial of cisplatinum. methotrexate, cisplatinum + methotrexate and cisplatinum + 5-FU in end stage squamous carcinoma of the head and neck. Br J Cancer 1992; 61: 311-5.
38. Jacobs C, Lyman G, Velez-Garcia E et al. A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 1992; 10: 257-63.
39. De Andrés L. Brunet J, Lopez-Pousa A et al. Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 1995; 13: 1493-500.
40. Kish J, Ensley J, Weaver A et al. A randomized trial of cisplatin (CACP) ÷ 5-fluorouracil (5-FU) infusion and CACP+ 5-FU bolus for recurrent and advanced squamous cell carcinoma of the head and neck. Cancer 1985; 56: 2740.
41. Vokes EE. Fluorouracil modulation in head and neck cancer. In Rustum YM (ed): Novel Approaches to Selective Treatments of Human Solid Tumors: Laboratory and Clinical Correlation. New York: Plenum Press 1993; 197-208.
42. Forastiere AA and Urba SG. Single agent paclitaxel and paclitaxel plus ifosfamide in the treatment of head and neck cancer. Semin Oncol 1995; 22: 24-7.
43. Verweij J, Alexiera-Figresch J, DeBoer MF. Ifosfamide in advanced head and neck cancer. A phase II study of the Rotterdam Cooperative Head and Neck Cancer Study Group. Eur J Cancer Clin Oncol 1988; 24: 795-6.
44. Kish JA, Weaver A, Jacobs J et al. Cisplatin and 5-fluorouracil infusion in patients with recurrent and disseminated epidermoid cancer of the head and neck. Cancer 1984; 53: 1819-24.
45. Clavel M, Vermorken JB, Cognetti F et al. Randomized comparison of cisplatin, methotrexate, bleomycin and vincristine (CABO) versus cisplatin and 5-fluorouracil (CF) versus cisplatin (C) in recurrent or metastatic squamous cell carcinoma of the head and neck. A phase III study of the EORTC Head and Neck Cancer Cooperative Group. Ann Oncol 1994; 5: 521-6.
46. Browman GP, Cronin L. Standard chemotherapy in squamous cell head and neck cancer: What we have learned from randomized trials. Semin Oncol 1994; 21: 311-9.
47. Vokes EE, Choi E, Schilsky RL et al. Cisplatin, fluorouracil, and high-dose leucovorin for recurrent or metastatic head and neck cancer. J Clin Oncol 1988; 6: 618-26.
48. Vlock DR, Johnson J, Myers E et al. Preliminary trial of nonrecombinant interferon in recurrent squamous cell carcinoma of the head and neck. Head Neck 1991; 13: 15-21.
49. Cascinu S, Fedeli A, Fedeli SL et al. Cisplatin, 5-fluorouracil and interferon alpha 2b for recurrent or metastatic head and neck cancer. Br J Cancer 1994; 69: 392-3.
50. Bensmaine A, Azli N, Domenge C et al. Cisplatin-5-FU modulation by alpha interferon 2b (IFN) in metastatic and/or recurrent head and neck squamous cell carcinoma (HNSCC). Ann Oncol 1992; 3 (Suppl 5): 153.
51. Hussain M, Benedetti J, Smith R et al. Alpha interferon (α-IFN) and 5-fluorouracil (5-FU) and cisplatin (cisplatin) in advanced squamous cell carcinoma of the head and neck (SCCHN): A Southwest Oncology Group (SWOG) phase II trial. Proc Am Soc Clin Oncol 1994; 13: 279.
52. Arquette MA, Mortimer JE, Loehrer PJ et al. A phase II Hoosier Oncology Group trial of interferon alpha-2b (IFN) added to cisplatin (cisplatin) and 5-fluorouracil (5-FU) in recurrent or metastatic head and neck cancer. Proc Am Soc Clin Oncol 1994; 13: 280.
53. Catimel G, Verweij J, Mattijssen V et al. Docetaxele (Taxotere): An active drug for the treatment of patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7.
54. Dreyfuss A, Clark J, Norris C et al. Taxotere for advanced incurable squamous cell carcinoma of head and neck. Proc Am Soc Clin Oncol 1994; 13: 287.
55. Gebbia V, Testa A, Valenza R et al. A pilot study of vinorelbine on a weekly schedule in recurrent and/or metastatic squamous cell carcinoma of the head and neck. Eur J Cancer 1993; 29A: 1358-9.
56. Gebbia V, Testa A, Valenza R et al. Vinorelbine plus cisplatin and 5-fluorouracil in recurrent and/or metastatic squamous cell head and neck carcinoma. Proc Am Soc Clin Oncol 1993; 12: 283 (Abstr 917).
57. Vokes EE, Rosenberg RK, Jahanzeb M et al. Multicenter phase II study of weekly oral vinorelbine for stage [V non-small cell lung cancer. J Clin Oncol 1995; 13: 637-44.
58. Catimel G, Vermorken JB. Clavel M et al. A phase II study of Gemcitabine (LY 188011) in patients with advanced squamous cell carcinoma of the head and neck. Ann Oncol 1994; 5: 533-7.
59. Robert F, Wheeler RH, Molthrop DC et al. Phase II study of topotecan in advanced head and neck cancer: Identification of an active new agent. Proc Am Soc Clin Oncol 1994; 13: 281 (Abstr 905).
60. Azli N, Fandi A, Bachouchi M et al. Final report of a phase II study of chemotherapy with bleomycin, epirubicin, and cisplatin for locally advanced and metastatic/recurrent undifferentiated carcinoma of the nasopharyngeal type. Cancer J Sci Am 1995; 1: 222-9.
61. Grandi C, Mingardo M, Guzzo M et al. Salvage surgery of cervical recurrences after neck dissection or radiotherapy. Head Neck 1993; 15: 292-5.
62. Viani L, Stell PM, Dalby JE et al. Recurrence after radiotherapy for glottic carcinoma. Cancer 1991; 67: 577-84.
63. Adelstein DJ. The community approach to salvage therapy for advanced head and neck cancer. Semin Oncol 1994; 21 (Suppl 7): 52-7.
64. Marcial VA, Hanley JA, Ydrach A et al. Tolerance of surgery after radical radiotherapy of carcinoma of the oropharynx. Cancer 1980; 46: 1910-2.
65. Mazer TM, Robbins KT, Mc Murtrey MJ et al. Resection of pulmonary metastases from squamous carcinoma of the head and neck. Am J Surg 1988; 156: 238-42.
66. Wang CC. Reirradiation of recurrent nasopharyngeal carcinoma. Treatment, techniques and results. Int J Radiat Oncol Biol Phys 1987; 13: 953-6.
67. Stevens KR Jr, Britsch A, Moss WT et al. High-dose reirradiation of head and neck cancer with curative intent. Int J Radiat Oncol Biol Phys 1993; 29: 687-98.
68. Wang CC. To reirradiate or not to reirradiate? Int J Radiat Oncol Biol Phys 1993; 29: 913.
69. Weichselbaum RR, Beckett MA, Schwartz JL et al. Radioresistant tumor cells are present in head and neck carcinomas that recur after radiotherapy. Int J Radiat Oncol Biol Phys 1988; 15: 575.
70. Vokes EE, Weichselbaum RR. Concomitant chemoradiotherapy: Rationale and clinical experience in patients with solid tumors. J Clin Oncol 1990; 8: 911-34.
71. Vokes EE. Interactions of chemotherapy and radiation. Semin Oncol 1993; 20: 70-6.
72. Vokes EE, Panje WR, Schilsky RL et al. Hydroxyurea, 5-fluorouracil and concomitant radiotherapy in poor prognosis head and neck cancer: A phase I-II study. J Clin Oncol 1989; 7: 761-8.
73. Vokes EE, Haraf DJ, Weichselbaum RR et al. Perspectives on combination chemotherapy with concomitant radiotherapy for poor-prognosis head and neck cancer. Semin Oncol 1992; 19: 47-56.
74. Vokes EE, Haraf DJ, Mick R et al. Intensified concomitant chemoradiotherapy with and without filgrastim for poor-prognosis head and neck cancer. J Clin Oncol 1994; 12: 2351-9.
75. Vokes EE, Stupp R, Haraf D et al. Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil and concomitant radiotherapy for poor prognosis head and neck cancer. Semin Oncol 1995; 22 (Suppl 6): 47-52.
76. Gandia D, Wibault P, Guillot T et al. Simultaneous chemoradiotherapy as salvage treatment in locoregional recurrences of squamous head and neck cancer patients. Head Neck 1993; 15: 15-23.
77. Weppelmann B, Wheeler RA, Peters GE et al. Treatment of recurrent head and neck cancer with 5-fluorouracil, hydroxyurea, and reirradiation. Int J Radiat Oncol Biol Phys 1992; 22: 1051-6.
78. Hartsell WF, Thomas CR Jr, Murthy AK et al. Pilot study for the evaluation of simultaneous cisplatin/5-fluorouracil infusion and limited radiation therapy in regionally recurrent head and neck cancer (EST P-C385). Am J Clin Oncol 1994; 17(4): 338-43.
79. O'Sullivan B, MacKillop W, Gilbert R et al. Controversies in the management of laryngeal cancer: Results of an international survey of patterns of care. Radiother Oncol 1994; 31: 23-32.
80. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993; 85: 95-111.
81. Stupp R, Weichselbaum RR, Vokes EE. Combined modality therapy of head and neck cancer. Semin Oncol 1994; 21: 349-58.
82. Kish J, Drelichman A, Jacobs J et al. Clinical trial of cisplatin and 5-FU infusion as initial treatment for advanced squamous cell carcinoma of the head and neck. Cancer Treat Rep 1982; 66: 471-6.
83. Rooney M, Kish J, Jacobs J et al. Improved complete response rate and survival in advanced head and neck cancer after three-course induction therapy with 120-hour 5-FU infusion and cisplatin. Cancer 1985; 55: 1123-8.
84. Thyss A, Schneider M, Santini J et al. Induction chemotherapy with cis-platinum and 5-fluorouracil for squamous cell carcinoma of the head and neck. Br J Cancer 1986; 54: 755-60.
85. Kies MS, Gordon LI, Hauck WW et al. Analysis of complete responders after initial treatment with chemotherapy in head and neck cancer. Laryngol Head Neck Surg 1985; 93: 199-205.
86. Forastiere AA. Randomized trials of induction chemotherapy: A critical review. Hematol/Oncol Clin North Am 1991; 5: 725-36.
87. Head and Neck Contracts Program. Adjuvant chemotherapy for advanced head and neck squamous carcinoma: Final report. Cancer 1987; 60: 301-11.
88. Jacobs C, Makuch R. Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: A subset analysis of the Head and Neck Contracts Program. J Clin Oncol 1990; 8: 838-47.
89. Schuller DE, Metch B, Stein DW et al. Preoperative chemotherapy in advanced resectable head and neck cancer: Final report of the Southwest Oncology Group. Laryngoscope 1988; 98: 1205-11.
90. The Department of Veterans Affairs Laryngeal Cancer Study Group. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 1991; 324: 1685-90.
91. Laramore GE, Scott CB, Al-Sarraf M et al. Adjuvant chemotherapy for resectable squamous cell carcinomas of the head and neck: Report on intergroup study. Int J Radiat Oncol Biol Phys 1992; 23: 705-13.
92. Paccagnella A, Orlando A, Marcniori C et al. Phase III trial of initial chemotherapy in stage III or IV head and neck cancers: A study by the Gruppo di Studio sui Tumori della Testa e del Collo. J Natl Cancer Inst 1994; 86: 265-72.
93. Lefebvre JL, Sahmoud T, for the EORTC Head and Neck Cancer Cooperative Group. Larynx preservation in hypopharynx squamous cell carcinoma: Preliminary results of a randomized study (EORTC 24891). Proc Am Soc Clin Oncol 1994; 13: 283 (Abstr 912).
94. Fandi A, Altun M, Azli N et al. Nasopharyngeal cancer: Epidemiology, staging, and treatment. Semin Oncol 1994; 21: 382-97.
95. Chan ATC, Teo PML, Leung TWT et al. A prospective randomized study of chemotherapy adjunctive to definitive radiotherapy in advanced nasopharyngeal carcinoma. Int J Radiat Oncol Biol Phys 1995; 33: 569-77.
96. Al-Sarraf M, McLaughlin PW. Nasopharynx carcinoma: Choice of treatment. Int J Radiat Oncol Biol Phys 1995; 33: 761-3.
97. Cvitkovic E. Neoadjuvant chemotherapy with epirubicin, cisplatin, bleomycin in undifferentiated nasopharyngeal cancer: Preliminary results of an international phase III trial. Proc Am Soc Clin Oncol 1994; 13: 283 (Abstr 915).
98. Vokes EE, Weichselbaum RR, Mich R et al. Favorable long-term survival following induction chemotherapy with PFL and concomitant chemoradiotherapy for locally advanced head and neck cancer. J Natl Cancer Inst 1992; 84: 877-81.
99. Dreyfuss AI, Clark JR, Wright JE. Continuous infusion high-dose leucovorin with 5-fluorouracil and cisplatin for untreated stage IV carcinoma of the head and neck. Ann Intern Med 1990; 112: 167-72.
100. Pfister DG, Bajorin D, Motzer R et al. Cisplatin, fluorouracil, and leucovorin. Increased toxicity without improved response in squamous cell head and neck cancer. Arch Otolaryngol Head Neck Surg 1994; 120 (1): 89-95.
101. Wendt TG, Hartenstein RC, Wustrow TP et al. Cisplatin, fluorouracil with leucovorin enhancement, and synchronous accelerated radiotherapy in the management of locally advanced head and neck cancer: A phase II study. J Clin Oncol 1989; 7: 471-6.
102. Vokes EE, Ratain MJ, Mick R et al. Cisplatin, fluorouracil and leucovorin augmented by interferon alpha-2B in head and neck cancer: A clinical and pharmacologic analysis. J Clin Oncol 1993; 11: 360-8.
103. Vokes EE, Kies M, Haraf DJ et al. Induction chemotherapy followed by concomitant chemoradiotherapy for advanced head and neck cancer: Impact on the natural history of the disease. J Clin Oncol 1995; 13: 876-83.
104. Zittoun J. Pharmacokinetics and in vitro studies of 1-leucovorin. Comparison with the d- and d,l-leucovorin. Ann Oncol 1993; 4(Suppl 2): S1-S5.
105. Schneider M, Etienne MC, Milano G et al. Phase II trial of cisplatin, fluorouracil, and pure folinic acid for locally advanced head and neck cancer: A pharmacokinetic and clinical survey. J Clin Oncol 1995; 13: 1656-62.
106. Vokes EE, Mick RR, Kies M et al. Fluorouracil pharmacodynamics of induction chemotherapy in advanced head and neck cancer Proc Am Soc Clin Oncol 1995; 14: 297.
107. Beck A, Etienne MC, Chéradame S et al. A role for dihydropyrimidine dehydrogenase and thymidylate synthase in tumour sensitivity to fluorouracil. Eur J Cancer 1994; 30A: 1517-22.
108. Lu Z, Zhang R, Diasio RB. Dihydropyrimidine dehydrogenase activity in human peripheral blood mononuclear cells and liver: Population characteristics, newly identified deficient patients, and clinical implication in 5-fluorouracil chemotherapy. Cancer Res 1993; 53: 5433-8.
109. Petit E, Milano G, Levi F et al. Circadian rhythm-varying plasma concentration of 5-fluorouracil during a five-day continuous venous infusion at a constant rate in cancer patients. Cancer Res 1988; 48: 1676-9.
110. Milano G, Etienne MC, Renee N et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994; 12: 1291-5.
111. Etienne MC, Cheradame S, Fischel JL et al. Response to fluorouracil therapy in cancer patients: The role of tumoral dihydropyrimidine dehydrogenase activity. J Clin Oncol 1995; 13: 1663-70.
112. Santini J, Milano G, Thyss A et al. 5-FU therapeutic monitoring with dose adjustment leads to improved therapeutic index in head and neck cancer. Br J Cancer 1989; 59: 287-90.
113. Jacobs C, Goffinet DR, Gofftinet L et al. Chemotherapy as a substitute for surgery in the treatment of advanced resectable head and neck cancer. A report from the Northern California Oncology Group. Cancer 1987; 60: 1178-83.
114. Urba SG, Forastiere AA, Wolf GT et al. Intensive induction chemotherapy and radiation for organ preservation in patients with advanced resectable head and neck carcinoma. J Clin Oncol 1994; 12: 946-53.
115. Kraus DH, Pfister DG, Harrison LB et al. Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. Otolaryngol Head Neck Surg 1994; 111: 31-7.
116. Armstrong J, Pfister D, Strong E et al. The management of the clinically positive neck as part of a larynx preservation approach, Int J Radiat Oncol Biol Phys 1993; 26: 759-65.
117. Van Putten WLJ, Vandersangen MJC, Hoekstra CJM et al. Dose, fractionation and overall treatment time in radiation therapy: The effects on local control for cancer of the larynx. Radiother Oncol 1994; 30: 97-108.
118. Pajak TF, Laramore GE, Marcial VA et al. Elapsed treatment days - a critical item for radiotherapy quality control review in head and neck trials: RTOG report, Int J Radiat Oncol Biol Phys 1991; 20: 13-20.
119. Corvo R, Giaretti W, Sanguineti G et al. In vivo cell kinetics in head and neck squamous cell carcinomas predicts local control and helps guide radiotherapy regimen. J Clin Oncol 1995; 13: 1843-50.
120. Horiot JC, Le-Fur R, Nguyen T et al. Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma: Final analysis of a randomized trial of the EORTC Cooperative Group of Radiotherapy. Radiother Oncol 1992; 25: 231-41.
121. Bush RS, Jenkin RDT, Alh WEC et al. Definitive evidence for hypoxic cells influencing cure in cancer therapy. Br J Cancer 1978; 37 (Suppl 3): 302.
122. Dische S. A review of hypoxic cell radiosensitization. Int J Radiat Oncol Biol Phys 1991; 20: 147.
123. Lee DJ, Pajak TF, Marcial VA et al. Results of an RTOG phase III trial (RTOG 85-27) comparing radiotherapy plus Etanidazole (SR-2508) with radiotherapy alone for locally advanced head and neck carcinomas. Int J Radiat Oncol Biol Phys 1994; 30: 212 (Abstr).
124. Byfield JE, Calabro-Jones P, Klisak I et al. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro combined 5-fluorouracil or Ftorafur and X-rays. Int J Radiat Oncol Biol Phys 1982; 8: 1923-33.
125. Tishler RB, Geard CR, Hall EJ et al. Taxol sensitizes human astrocytoma cells to radiation. Cancer Res 1992; 52: 3495-3497.
126. Vokes EE. Concomitant chemoradiotherapy for solid tumors: Rationale and clinical experience. Proceedings of a symposium. Semin Oncol 1992; 19(Suppl 11): 1-108.
127. Lo TC, Wiley AL, Jr, Ansfield FJ et al. Combined radiation therapy and 5-fluorouracil for advanced squamous cell carcinoma of the oral cavity and oropharynx: A randomized study. Am J Roentgenol 1976; 126: 229-35.
128. Byfield JE, Sharp TR, Frankel SS et al. Phase I and II trial of five-day infused 5-fluorouracil and radiation in advanced cancer of the head and neck. J Clin Oncol 1984; 2: 406-13.
129. Browman GP, Cripps C, Hudson DI et al. Placebo-controlled randomized trial of infusional fluorouracil during standard radiotherapy in locally advanced head and neck cancer. J Clin Oncot 1994; 12: 2648-53.
130. Al-Sarraf M, Pajak T, Marcial VA et al. Concurrent radiotherapy and chemotherapy with cisplatinum in inoperable mucosal squamous cell carcinoma of the head and neck: An RTOG study. Cancer 1987: 59: 259-65.
131. Bachaud JM, David JM, Boussin G et al. Combined postoperative radiotherapy and weekly cisplatin infusion for locally advanced squamous cell carcinoma of the head and neck: Preliminary report of a randomized trial. Int J Radiat Oncol Biol Phys 1991; 20: 243-6.
132. Glicksman AS, Slotman G, Doolittle C et al. Concurrent cis-platinum and radiation with or without surgery for advanced head and neck cancer. Int J Radiat Oncol Biol Phys 1994; 30: 1043-50.
133. Coughlin CT, Richmond RC. Biologic and clinical developments of cisplatin combined with radiation: Concepts, utility, projections of new trials, and the emergence of carboplatin. Semin Oncol 1989; 16(Suppl 4): 31-43.
134. Aisner J, Hiponia D, Conley B et al. Combined modalities in the treatment of head and neck cancers. Semin Oncol 1995; 22(3): 28-34.
135. Gupta NK, Pointon RC, Wilkinson PM. A randomized clinical trial to contrast radiotherapy with radiotherapy and methotrexate given synchronously in head and neck cancer. Clin Radiol 1987; 38: 575-81.
136. Fu KK, Philips TL, Silverberg IJ et al. Combined RT and CT with bleomycin and methotrexate for advanced inoperable head and neck cancer: Update of a Northern California Oncology Group randomized trial. J Clin Oncol 1987; 5: 1410-8.
137. Eschwege F, Sancho-Garnier H, Gerard GP et al. Ten year results of a randomized trial comparing radiotherapy and concomitant bleomycin to radiotherapy alone in epidermoid carcinomas of the oropharynx: Experience of the EORTC. Monogr Natl Cancer Inst 1988; 6: 275-8.
138. Weissberg JB, Son YH, Papac RJ et al. Randomized clinical trial of mitomycin-C as an adjunct to radiotherapy in head and neck cancer. Int J Radiat Oncol Biol Phys 1989; 17: 3-9.
139. Haffy BG, Sou KH, Sasaki CT et al. Mitomycin C as an adjunct to postoperative radiation therapy in squamous cell carcinoma of the head and neck: Results from two randomized clinical trials. Int J Radiat Oncol Biol Phys 1993; 27: 241-50.
140. Vokes EE, Haraf DJ, Stenson K et al. The role of paclitaxel in the treatment of head and neck cancer. Semin Oncol 1995; 12: 8-12.
141. Denham JW, Abbott RL. Concurrent cisplatin, infusional fluorouracil and conventionally fractionated radiation therapy in head and neck cancer: Dose limiting mucosal toxicity. J Clin Oncol 1991; 9: 458-63.
142. Keane TJ, Cummings BJ, O'Sullivan B et al. A randomized trial of radiation therapy compared to split course radiation therapy combined with mitomycin-C and 5-fluorouracil as initial treatment for advanced laryngeal and hypopharyngeal squamous carcinoma. Int J Radiat Oncol Biol Phys 1993; 25: 613-8.
143. Taylor SG IV, Murthy AK, Calderelli DD et al. Combined simultaneous cisplatin/fluorouracil chemotherapy and split course radiation in head and neck cancer. J Clin Oncol 1989; 7: 846-56.
144. Adelstein DJ, Sharan VM, Earle AS et al. Long-term results after chemoradiotherapy for locally confined squamous-cell head and neck cancer. Am J Clin Oncol 1990; 13: 440-7.
145. Adelstein DJ, Kalish LA, Adams GL et al. Concurrent radiation therapy and chemotherapy for locally unresectable squamous cell head and neck cancer: An Eastern Cooperative Oncology Group Pilot Study. J Clin 1993; 11: 2136-42.
146. Looney WB. Special lecture: Alternating chemotherapy and radiotherapy. Monogr Natl Cancer Inst 1988; 6: 85-92.
147. Merlano M, Corvo R, Marganno G et al. Combined chemotherapy and radiation therapy in advanced inoperable squamous cell carcinoma of the head and neck: The final report of a randomized trial. Cancer 1991; 67: 915-21.
148. Merlano M, Grimaldi A, Benasso M et al. Alternating cisplatin-5-fluorouracil and radiotherapy in head and neck cancer. Am J Clin Oncol 1988; 11: 538-42.
149. Merlano M, Vitale V, Rosso R et al. Treatment of advanced squamous cell carcinoma of the head and neck with alternating chemotherapy and radiotherapy. N Engl J Med 1992; 327; 1115-21.
150. Leyvraz S, Pasche P, Bauer J et al. Rapidly alternating chemotherapy and hyperfractionated radiotherapy in the management of locally advanced head and neck carcinoma: Four-year results of a phase I/II study. J Clin Oncol 1994; 12: 1876-85.
151. Vokes EE, Haraf DJ, Mick R et al. Concomitant chemoradiotherapy for intermediate stage head and neck cancer (HNC). Proc Am Soc Clin Oncol 1994; 13: 282 (Abstr 909).
152. Kies MS, Haraf DJ, Mittal B et al. Intensive combined therapy with concomitant 5-FU, Hydroxyurea, BID radiation and cisplatin (C-FHX) for locally advanced squamous cancer of the head and neck. Proceedings of the Fifth International Congress on Anti-Cancer Chemotherapy, 1995. Paris, France. (Abstr O200).